Elekta Reports Quarterly Revenue of $372.30M Amid Financial Metrics Review
What happened
Elekta reported $372.30 million in revenue for the quarter, alongside $0.07 in earnings per share. The company reported a negative net margin of 2.38% and a current ratio of 0.86. Analysts previously upgraded shares of Elekta from a “strong sell” to a “hold” rating in July.
From tickerreport.com
Why it matters
The financial results provide insight into the performance of the Swedish medical technology company, which is currently receiving a loan of up to €100 million from the European Investment Bank. The company also utilizes its advanced cancer care technology within Karnataka's healthcare infrastructure.
From tickerreport.com
Who's involved
- ElektaSwedish medical technology company reporting financial results
- SwedenCountry where Elekta is based
- European Investment BankBody providing a loan of up to €100 million to Elekta
- KarnatakaRegion where Elekta deploys advanced cancer care technology
- OmnicellHealthcare technology company characterized as a small-cap peer to Elekta
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- KarnatakaSpeculative
Demand for Elekta's advanced cancer care technology might increase or decrease based on the company's financial stability.
- European Investment BankSpeculative
The European Investment Bank's lending portfolio could be affected by the financial performance of Elekta.